tetano
Editor, Senior Moderator
EBioMedicine. 2017 Jul 13. pii: S2352-3964(17)30283-9. doi: 10.1016/j.ebiom.2017.07.010. [Epub ahead of print]
[h=1]C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases.[/h] Gao R[SUP]1[/SUP], Wang L[SUP]2[/SUP], Bai T[SUP]2[/SUP], Zhang Y[SUP]2[/SUP], Bo H[SUP]2[/SUP], Shu Y[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Severe influenza diseases with high mortality have been frequently reported, especially in those patients infected with avian influenza A (H5N1, H7N9 or H10N8) or during a pandemic. Respiratory distress, which is attributed to alveolar damage associated with immunopathological lesions, is the most common cause of death. There is a wealth of information on pathogenesis or treatment options. In this study, we showed that high levels of C-reactive protein (CRP) were induced and correlated with complement activation in patients infected with severe influenza A (H5N1, H7N9 or H10N8), and higher levels were induced in fatal patients than in survivors. CRP treatment enhanced the phagocytosis of monocytes THP-1 to H5N1 virus as well as the expression of proinflammatory cytokines or apoptosis-associated genes in THP-1 cells or pneumocytes A-549 respectively. CRP may link to proinflammatory mediators contributing to activation of complement and boosting inflammatory response in severe influenza infections. Compound 1,6-bis(phosphocholine)-hexane improved the severity and mortality of mice infected with lethal influenza virus significantly. These observations showed that CRP is involved in deterioration of severe influenza diseases, and indicated a substantial candidate molecule for immunotherapy of severe influenza diseases.
Copyright ? 2017 The Authors. Published by Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] C-reactive protein; Complement response; Immunotherapy; Severe influenza infection
PMID: 28734805 DOI: 10.1016/j.ebiom.2017.07.010
Free full text
[h=1]C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases.[/h] Gao R[SUP]1[/SUP], Wang L[SUP]2[/SUP], Bai T[SUP]2[/SUP], Zhang Y[SUP]2[/SUP], Bo H[SUP]2[/SUP], Shu Y[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Severe influenza diseases with high mortality have been frequently reported, especially in those patients infected with avian influenza A (H5N1, H7N9 or H10N8) or during a pandemic. Respiratory distress, which is attributed to alveolar damage associated with immunopathological lesions, is the most common cause of death. There is a wealth of information on pathogenesis or treatment options. In this study, we showed that high levels of C-reactive protein (CRP) were induced and correlated with complement activation in patients infected with severe influenza A (H5N1, H7N9 or H10N8), and higher levels were induced in fatal patients than in survivors. CRP treatment enhanced the phagocytosis of monocytes THP-1 to H5N1 virus as well as the expression of proinflammatory cytokines or apoptosis-associated genes in THP-1 cells or pneumocytes A-549 respectively. CRP may link to proinflammatory mediators contributing to activation of complement and boosting inflammatory response in severe influenza infections. Compound 1,6-bis(phosphocholine)-hexane improved the severity and mortality of mice infected with lethal influenza virus significantly. These observations showed that CRP is involved in deterioration of severe influenza diseases, and indicated a substantial candidate molecule for immunotherapy of severe influenza diseases.
Copyright ? 2017 The Authors. Published by Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] C-reactive protein; Complement response; Immunotherapy; Severe influenza infection
PMID: 28734805 DOI: 10.1016/j.ebiom.2017.07.010
Free full text